NovaBay Pharmaceuticals (NBY) Earnings Date, Estimates & Call Transcripts → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free NBY Stock Alerts $0.08 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share EarningsStock AnalysisChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort Interest Earnings SummaryLatest Earnings DateMar. 26EstimatedActual EPS (Mar. 26) -$0.95 Missed By -$0.95 Get NovaBay Pharmaceuticals Earnings AlertsEnter your email address below to receive the latest news and earnings results for NBY and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueNBY Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.NBY Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> NovaBay Pharmaceuticals Analyst EPS EstimatesCurrent Year EPS Consensus Estimate:($2.54) EPSNext Year EPS Consensus Estimate: ($0.55) EPSNBY Earnings Date and InformationNovaBay Pharmaceuticals last released its quarterly earnings data on March 26th, 2024. The biopharmaceutical company reported ($0.95) EPS for the quarter. The business had revenue of $3.73 million for the quarter. NovaBay Pharmaceuticals has generated ($9.95) earnings per share over the last year (($9.95) diluted earnings per share). Earnings for NovaBay Pharmaceuticals are expected to grow in the coming year, from ($2.54) to ($0.55) per share. Read More NovaBay Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript3/26/2024Q4 2023-($0.95)($0.95)($0.57)-$3.73 million11/9/2023Q3 2023-($0.37)($0.37)($0.37)-$3.27 million8/10/2023Q2 2023-($1.27)($1.27)($1.27)-$4.61 million5/11/2023Q1 2023-($0.85)($0.85)($0.85)-$3.12 million 5/11/2023Q1 2023-($0.85)($0.85)($0.85)-$3.12 million5/11/2023Q1 2023-($0.85)($0.85)($0.85)-$3.12 million Get the Latest News and Ratings for NBY and Related StocksEnter your email address below to receive the latest news and analysts' ratings for NovaBay Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 5/11/2023Q1 2023-($0.85)($0.85)($0.85)-$3.12 million5/11/2023Q1 2023-($0.85)($0.85)($0.85)-$3.12 million5/11/2023Q1 2023-($0.85)($0.85)($0.85)-$3.12 million5/11/2023Q1 2023-($0.85)($0.85)($0.85)-$3.12 million5/11/2023Q1 2023-($0.85)($0.85)($0.85)-$3.12 million5/11/2023Q1 2023-($0.85)($0.85)($0.85)-$3.12 million5/11/2023Q1 2023-($0.85)($0.85)($0.85)-$3.12 million5/11/2023Q1 2023-($0.85)($0.85)($0.85)-$3.12 million5/11/2023Q1 2023-($0.85)($0.85)($0.85)-$3.12 million5/11/2023Q1 2023-($0.85)($0.85)($0.85)-$3.12 million5/11/2023Q1 2023-($0.85)($0.85)($0.85)-$3.12 million5/11/2023Q1 2023-($0.85)($0.85)($0.85)-$3.12 million5/11/2023Q1 2023-($0.85)($0.85)($0.85)-$3.12 million5/11/2023Q1 2023-($0.85)($0.85)($0.85)-$3.12 million5/11/2023Q1 2023-($0.85)($0.85)($0.85)-$3.12 million5/11/2023Q1 2023-($0.85)($0.85)($0.85)-$3.12 million5/11/2023Q1 2023-($0.85)($0.85)($0.85)-$3.12 million5/11/2023Q1 2023-($0.85)($0.85)($0.85)-$3.12 million5/11/2023Q1 2023-($0.85)($0.85)($0.85)-$3.12 million3/30/2023Q4 2022-($4.33)($4.33)($4.33)-$3.64 million3/30/2023Q4 2022-($4.33)($4.33)($4.33)-$3.64 million3/30/2023Q4 2022-($4.33)($4.33)($4.33)-$3.64 million3/30/2023Q4 2022-($4.33)($4.33)($4.33)-$3.64 million3/30/2023Q4 2022-($4.33)($4.33)($4.33)-$3.64 million3/30/2023Q4 2022-($4.33)($4.33)($4.33)-$3.64 million3/30/2023Q4 2022-($4.33)($4.33)($4.33)-$3.64 million3/30/2023Q4 2022-($4.33)($4.33)($4.33)-$3.64 million3/30/2023Q4 2022-($4.33)($4.33)($4.33)-$3.64 million3/30/2023Q4 2022-($4.33)($4.33)($4.33)-$3.64 million3/30/2023Q4 2022-($4.33)($4.33)($4.33)-$3.64 million3/30/2023Q4 2022-($4.33)($4.33)($4.33)-$3.64 million3/30/2023Q4 2022-($4.33)($4.33)($4.33)-$3.64 million3/30/2023Q4 2022-($4.33)($4.33)($4.33)-$3.64 million3/30/2023Q4 2022-($4.33)($4.33)($4.33)-$3.64 millionBetter than Bitcoin? The Biotech Stock with 46,751% Potential (Ad)4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>>3/30/2023Q4 2022-($4.33)($4.33)($4.33)-$3.64 million3/30/2023Q4 2022-($4.33)($4.33)($4.33)-$3.64 million3/30/2023Q4 2022-($4.33)($4.33)($4.33)-$3.64 million3/30/2023Q4 2022-($4.33)($4.33)($4.33)-$3.64 million3/30/2023Q4 2022-($4.33)($4.33)($4.33)-$3.64 million3/30/2023Q4 2022-($4.33)($4.33)($4.33)-$3.64 million3/30/2023Q4 2022-($4.33)($4.33)($4.33)-$3.64 million11/14/2022Q3 2022-($3.50)($3.50)($3.50)-$3.83 million11/14/2022Q3 2022-($3.50)($3.50)($3.50)-$3.83 million11/14/2022Q3 2022-($3.50)($3.50)($3.50)-$3.83 million11/14/2022Q3 2022-($3.50)($3.50)($3.50)-$3.83 million11/14/2022Q3 2022-($3.50)($3.50)($3.50)-$3.83 million11/14/2022Q3 2022-($3.50)($3.50)($3.50)-$3.83 million11/14/2022Q3 2022-($3.50)($3.50)($3.50)-$3.83 million11/14/2022Q3 2022-($3.50)($3.50)($3.50)-$3.83 million11/14/2022Q3 2022-($3.50)($3.50)($3.50)-$3.83 million11/14/2022Q3 2022-($3.50)($3.50)($3.50)-$3.83 million11/14/2022Q3 2022-($3.50)($3.50)($3.50)-$3.83 million11/14/2022Q3 2022-($3.50)($3.50)($3.50)-$3.83 million11/14/2022Q3 2022-($3.50)($3.50)($3.50)-$3.83 million11/14/2022Q3 2022-($3.50)($3.50)($3.50)-$3.83 million11/14/2022Q3 2022-($3.50)($3.50)($3.50)-$3.83 million11/14/2022Q3 2022-($3.50)($3.50)($3.50)-$3.83 million11/14/2022Q3 2022-($3.50)($3.50)($3.50)-$3.83 million11/14/2022Q3 2022-($3.50)($3.50)($3.50)-$3.83 million11/14/2022Q3 2022-($3.50)($3.50)($3.50)-$3.83 million11/14/2022Q3 2022-($3.50)($3.50)($3.50)-$3.83 million11/14/2022Q3 2022-($3.50)($3.50)($3.50)-$3.83 million11/14/2022Q3 2022-($3.50)($3.50)($3.50)-$3.83 million11/14/2022Q3 2022-($3.50)($3.50)($3.50)-$3.83 million8/11/2022Q2 2022-($1.40)($1.40)($1.40)-$3.05 million8/11/2022Q2 2022-($1.40)($1.40)($1.40)-$3.05 million8/11/2022Q2 2022-($1.40)($1.40)($1.40)-$3.05 million8/11/2022Q2 2022-($1.40)($1.40)($1.40)-$3.05 million8/11/2022Q2 2022-($1.40)($1.40)($1.40)-$3.05 million8/11/2022Q2 2022-($1.40)($1.40)($1.40)-$3.05 million8/11/2022Q2 2022-($1.40)($1.40)($1.40)-$3.05 million8/11/2022Q2 2022-($1.40)($1.40)($1.40)-$3.05 million8/11/2022Q2 2022-($1.40)($1.40)($1.40)-$3.05 million8/11/2022Q2 2022-($1.40)($1.40)($1.40)-$3.05 million8/11/2022Q2 2022-($1.40)($1.40)($1.40)-$3.05 million8/11/2022Q2 2022-($1.40)($1.40)($1.40)-$3.05 million8/11/2022Q2 2022-($1.40)($1.40)($1.40)-$3.05 million8/11/2022Q2 2022-($1.40)($1.40)($1.40)-$3.05 million8/11/2022Q2 2022-($1.40)($1.40)($1.40)-$3.05 million8/11/2022Q2 2022-($1.40)($1.40)($1.40)-$3.05 million8/11/2022Q2 2022-($1.40)($1.40)($1.40)-$3.05 million8/11/2022Q2 2022-($1.40)($1.40)($1.40)-$3.05 million8/11/2022Q2 2022-($1.40)($1.40)($1.40)-$3.05 million8/11/2022Q2 2022-($1.40)($1.40)($1.40)-$3.05 millionBetter than Bitcoin? The Biotech Stock with 46,751% Potential (Ad)4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>>8/11/2022Q2 2022-($1.40)($1.40)($1.40)-$3.05 million8/11/2022Q2 2022-($1.40)($1.40)($0.04)-$3.05 million8/11/2022Q2 2022-($0.04)($0.04)($0.04)-$3.05 million3/29/2022Q4 2021-($0.02)($0.02)($0.02)-$2.64 million3/29/2022Q4 2021-($0.70)($0.70)($0.70)-$2.64 million3/29/2022Q4 2021-($0.70)($0.70)($0.70)-$2.64 million3/29/2022Q4 2021-($0.70)($0.70)($0.70)-$2.64 million3/29/2022Q4 2021-($0.70)($0.70)($0.70)-$2.64 million3/29/2022Q4 2021-($0.70)($0.70)($0.70)-$2.64 million3/29/2022Q4 2021-($0.70)($0.70)($0.70)-$2.64 million3/29/2022Q4 2021-($0.70)($0.70)($0.70)-$2.64 million3/29/2022Q4 2021-($0.70)($0.70)($0.70)-$2.64 million3/29/2022Q4 2021-($0.70)($0.70)($0.70)-$2.64 million3/29/2022Q4 2021-($0.70)($0.70)($0.70)-$2.64 million3/29/2022Q4 2021-($0.70)($0.70)($0.70)-$2.64 million3/29/2022Q4 2021-($0.70)($0.70)($0.70)-$2.64 million3/29/2022Q4 2021-($0.70)($0.70)($0.70)-$2.64 million3/29/2022Q4 2021-($0.70)($0.70)($0.02)-$2.64 million 3/29/2022Q4 2021-($0.70)($0.70)($0.70)-$2.64 million3/29/2022Q4 2021-($0.70)($0.70)($0.70)-$2.64 million3/29/2022Q4 2021-($0.70)($0.70)($0.70)-$2.64 million3/29/2022Q4 2021-($0.70)($0.70)($0.70)-$2.64 million3/29/2022Q4 2021-($0.70)($0.70)($0.70)-$2.64 million3/29/2022Q4 2021-($0.70)($0.70)($0.70)-$2.64 million3/29/2022Q4 2021-($0.70)($0.70)($0.70)-$2.64 million3/29/2022Q4 2021-($0.70)($0.70)($0.70)-$2.64 million11/11/2021Q3 2021-($1.75)($1.75)($1.75)-$1.84 million11/11/2021Q3 2021-($1.75)($1.75)($1.75)-$1.84 million11/11/2021Q3 2021-($1.75)($1.75)($1.75)-$1.84 million11/11/2021Q3 2021-($1.75)($1.75)($1.75)-$1.84 million11/11/2021Q3 2021-($1.75)($1.75)($1.75)-$1.84 million11/11/2021Q3 2021-($1.75)($1.75)($1.75)-$1.84 million11/11/2021Q3 2021-($1.75)($1.75)($1.75)-$1.84 million11/11/2021Q3 2021-($1.75)($1.75)($1.75)-$1.84 million11/11/2021Q3 2021($1.40)($1.75)($0.35)($0.05)-$1.84 million 11/11/2021Q3 2021-($1.75)($1.75)($1.75)-$1.84 million11/11/2021Q3 2021-($1.75)($1.75)($1.75)-$1.84 million11/11/2021Q3 2021-($1.75)($1.75)($1.75)-$1.84 million11/11/2021Q3 2021-($1.75)($1.75)($1.75)-$1.84 million11/11/2021Q3 2021-($1.75)($1.75)($1.75)-$1.84 million11/11/2021Q3 2021-($1.75)($1.75)($1.75)-$1.84 million11/11/2021Q3 2021-($1.75)($1.75)($1.75)-$1.84 million11/11/2021Q3 2021-($1.75)($1.75)($1.75)-$1.84 million11/11/2021Q3 2021-($1.75)($1.75)($1.75)-$1.84 million11/11/2021Q3 2021-($1.75)($1.75)($1.75)-$1.84 million11/11/2021Q3 2021-($1.75)($1.75)($1.75)-$1.84 million11/11/2021Q3 2021-($1.75)($1.75)($1.75)-$1.84 million11/11/2021Q3 2021-($1.75)($1.75)($1.75)-$1.84 million11/11/2021Q3 2021-($0.05)($0.05)($0.05)-$1.84 million8/12/2021Q2 2021-($0.04)($0.04)($0.04)-$2.13 millionBetter than Bitcoin? The Biotech Stock with 46,751% Potential (Ad)4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>>8/12/2021Q2 2021-($1.40)($1.40)($1.40)-$2.13 million8/12/2021Q2 2021-($1.40)($1.40)($1.40)-$2.13 million8/12/2021Q2 2021-($1.40)($1.40)($1.40)-$2.13 million8/12/2021Q2 2021-($1.40)($1.40)($1.40)-$2.13 million8/12/2021Q2 2021-($1.40)($1.40)($1.40)-$2.13 million8/12/2021Q2 2021-($1.40)($1.40)($1.40)-$2.13 million8/12/2021Q2 2021-($1.40)($1.40)($1.40)-$2.13 million8/12/2021Q2 2021-($1.40)($1.40)($1.40)-$2.13 million8/12/2021Q2 2021-($1.40)($1.40)($1.40)-$2.13 million8/12/2021Q2 2021-($1.40)($1.40)($1.40)-$2.13 million8/12/2021Q2 2021-($1.40)($1.40)($1.40)-$2.13 million8/12/2021Q2 2021-($1.40)($1.40)($1.40)-$2.13 million8/12/2021Q2 2021-($1.40)($1.40)($1.40)-$2.13 million8/12/2021Q2 2021($1.40)($1.40)-($0.04)-$2.13 million 8/12/2021Q2 2021-($1.40)($1.40)($1.40)-$2.13 million8/12/2021Q2 2021-($1.40)($1.40)($1.40)-$2.13 million8/12/2021Q2 2021-($1.40)($1.40)($1.40)-$2.13 million8/12/2021Q2 2021-($1.40)($1.40)($1.40)-$2.13 million8/12/2021Q2 2021-($1.40)($1.40)($1.40)-$2.13 million8/12/2021Q2 2021-($1.40)($1.40)($1.40)-$2.13 million8/12/2021Q2 2021-($1.40)($1.40)($1.40)-$2.13 million8/12/2021Q2 2021-($1.40)($1.40)($1.40)-$2.13 million5/6/2021Q1 2021-($1.40)($1.40)($1.40)-$1.81 million5/6/2021Q1 2021-($1.40)($1.40)($1.40)-$1.81 million5/6/2021Q1 2021-($1.40)($1.40)($1.40)-$1.81 million5/6/2021Q1 2021-($1.40)($1.40)($1.40)-$1.81 million5/6/2021Q1 2021-($1.40)($1.40)($1.40)-$1.81 million5/6/2021Q1 2021-($1.40)($1.40)($1.40)-$1.81 million5/6/2021Q1 2021-($1.40)($1.40)($1.40)-$1.81 million5/6/2021Q1 2021-($1.40)($1.40)($1.40)-$1.81 million5/6/2021Q1 2021($1.40)($1.40)-($0.04)-$1.81 million 5/6/2021Q1 2021-($1.40)($1.40)($1.40)-$1.81 million5/6/2021Q1 2021-($1.40)($1.40)($1.40)-$1.81 million5/6/2021Q1 2021-($1.40)($1.40)($1.40)-$1.81 million5/6/2021Q1 2021-($1.40)($1.40)($1.40)-$1.81 million5/6/2021Q1 2021-($1.40)($1.40)($1.40)-$1.81 million5/6/2021Q1 2021-($1.40)($1.40)($1.40)-$1.81 million5/6/2021Q1 2021-($1.40)($1.40)($1.40)-$1.81 million5/6/2021Q1 2021-($1.40)($1.40)($1.40)-$1.81 million5/6/2021Q1 2021-($1.40)($1.40)($1.40)-$1.81 million5/6/2021Q1 2021-($1.40)($1.40)($1.40)-$1.81 million5/6/2021Q1 2021-($1.40)($1.40)($1.40)-$1.81 million5/6/2021Q1 2021-($1.40)($1.40)($1.40)-$1.81 million5/6/2021Q1 2021-($1.40)($1.40)($1.40)-$1.81 million5/6/2021Q1 2021-($0.04)($0.04)($0.04)-$1.81 million NovaBay Pharmaceuticals Earnings - Frequently Asked Questions When did NovaBay Pharmaceuticals announce their last quarterly earnings? NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) last announced its quarterly earning data on Tuesday, March 26, 2024. Learn more on NBY's earnings history. How much revenue does NovaBay Pharmaceuticals generate each year? NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) has a recorded annual revenue of $14.40 million. How much profit does NovaBay Pharmaceuticals generate each year? NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) has a recorded net income of -$10.61 million. NBY has generated -$9.95 earnings per share over the last four quarters. What is NovaBay Pharmaceuticals's EPS forecast for next year? NovaBay Pharmaceuticals's earnings are expected to grow from ($2.54) per share to ($0.55) per share in the next year. More Earnings Resources from MarketBeat Related Companies: NMTR Earnings APVO Earnings BTTX Earnings ATHX Earnings MOTS Earnings XSNX Earnings SKVI Earnings AMPE Earnings ALLR Earnings VIVXF Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future OutlookCSX Co.: The Railroad Powering Ahead with an Earnings Beat What's Driving Tesla Lower Ahead of its Earnings?Blackrock vs. State Street: Earnings in a Volatile MarketWhat to Expect From the Q1 Earnings Reporting SeasonLululemon Stock Implodes Post Earnings, Guidance Muted This page (NYSEAMERICAN:NBY) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyThe World's First "$20 Trillion Drug?"Behind the MarketsA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovaBay Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
